ORTHO-NOVUM 7/7/7-21
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-21 (ORTHO-NOVUM 7/7/7-21).
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
| Metabolism | Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation. |
| Excretion | Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation. |
| Half-life | Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days. |
| Protein binding | Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin. |
| Volume of Distribution | Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone. |
| Onset of Action | Oral: contraceptive effect requires 7 days of consistent dosing; peak hormone levels at 1-2 hours. |
| Duration of Action | Oral: 24-hour dosing interval; contraceptive protection persists with each daily pill; withdrawal bleed during placebo week. |
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR 30-89 mL/min). Not recommended for severe renal impairment (GFR <30 mL/min) due to potential fluid retention and electrolyte disturbances. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity. |
| Pediatric use | Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen. |
| Geriatric use | Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-21 (ORTHO-NOVUM 7/7/7-21).
| Breastfeeding | Combined hormonal contraceptives may reduce milk production and quality, especially in early postpartum. Small amounts of estrogen and progestin are excreted in breast milk; the M/P ratio is not well defined for this specific formulation. Use is generally not recommended during breastfeeding, particularly before weaning or beyond 6 weeks postpartum when milk supply is established. Alternatives (progestin-only) are preferred. |
| Teratogenic Risk | Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
["High risk of arterial or venous thrombotic diseases (e.g., known thrombophilia, history of DVT/PE, cerebrovascular disease, coronary artery disease)","Current or history of breast cancer or other estrogen-sensitive cancer","Hepatic adenoma or carcinoma, or active liver disease","Undiagnosed abnormal uterine bleeding","Pregnancy","Hypersensitivity to any component","Smoking and age >35 years","Hypertension uncontrolled or with vascular disease","Migraine with aura if >35 years","Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease"]
| Precautions | ["Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Hepatic disease (e.g., jaundice, liver tumors)","Hypertension","Carbohydrate and lipid metabolism effects","Headache/migraine","Bleeding irregularities","Depression","Gallbladder disease","Hereditary angioedema","Pregnancy and postpartum use","Ophthalmic complaints (contact lens intolerance, retinal thrombosis)"] |
Loading safety data…
| Fetal Monitoring | Before initiating, rule out pregnancy. During use, monitor for signs of pregnancy if missed pills. No routine fetal monitoring required if not pregnant. If inadvertent use during pregnancy, consider ultrasound for fetal anatomy. |
| Fertility Effects | ORTHO-NOVUM 7/7/7-21 is used for contraception and reversibly suppresses ovulation. Return to fertility may be delayed up to a few months after discontinuation. No permanent effects on fertility. |